Smoking is a leading cause of death, and genetic variation contributes to smoking behaviors. Identifying genes and sets of genes that contribute to risk for addiction is necessary to prioritize targets for functional characterization and for personalized medicine.
INTRODUCTION:
Smoking is one of the most prominent causes of death in the United States, leading to numerous diseases and shortened life expectancy 1 . While the majority of smokers report a desire to quit, very few are able 2 . Furthermore, although smoking rates have decreased, other forms of nicotine consumption are rapidly growing, such as adolescent vaping 3 , demonstrating a pressing need to characterize the underlying biology of nicotine use and smoking to reduce subsequent premature death.
Abundant evidence indicates that up to 50% of the phenotypic variance in nicotine dependence is due to genetic factors [4] [5] [6] . In addition to this evidence from twin, adoption and family studies, genomewide association studies (GWAS) have begun to identify variants associated with smoking behaviors 7, 8 , providing insights into the genetic etiology of smoking and nicotine dependence. A key finding from such studies has been the high polygenicity of these traits -Liu et al. 7 found over two hundred conditionally independent loci throughout the genome that influenced smoking initiation, escalation, and cessation using over 1.2 million individuals, with additional loci expected to be identified as sample sizes increase.
Efficient genotyping and disease-specific arrays have been developed with the aim of identifying particular variants to use in individualized therapies through predictive genetic models 9 . To this end, the Smokescreen Genotyping Array was developed to tag over 1,000 addiction-related genes, identified through expert knowledge, bioinformatic databases, and previous studies 9 . These genes are thought to be strongly associated with addiction, and specifically nicotine use, behaviors.
Nicotinic acetylcholine receptors (nAChRs), which are bound by nicotine, play a key role in smoking behaviors and have been extensively investigated both in human population samples and in functional mouse models. In particular, the nAChR alpha 5 subunit (CHRNA5), which is bound by nicotine, is one of the most widely studied genes related to addiction, with replicated GWAS associations 7, 8, 10 and functional characterization in the mouse 11, 12 . Identifying the key genes that intracellularly interact with them and whether they contribute to heritable variation in smoking phenotypes can lead to biological insight and potentially novel therapeutic targets. Melroy-Greif et al. 13 performed an extensive literature search, in collaboration with experts in the field of nicotinic acetylcholine receptor (nAChR) research, to identify a set of 107 such genes involved in the upregulation, function, processing, and downstream effects of nAChR signaling (only 36 of these overlap with the Smokescreen Array gene set). Melroy-Greif et al. 13 posited that this set of genes that are involved in nAChR upregulation, known to occur in reponse to nicotine exposure, play a role in smoking behaviors. While Melroy-Greif et al. 13 did not find significant gene set associations with smoking phenotypes, GWAS sample sizes have since increased dramatically 7 , leading to greater statistical power to detect such associations.
Understanding which genes and sets of genes are associated with smoking phenotypes may help prioritize future functional studies in model organisms 14 and so remains an important goal. These two sets of genes provide a starting point to prioritize potential targets, but the high degree of polygenicity of smoking behaviors 7 raises the question of whether such genes are more strongly associated or enriched than the rest of the genome.
We sought here to assess whether and the degree to which these two sets of genes ("Smokescreen" and "Nicotinic" receptor gene sets) are associated with smoking phenotypes. Using the most recent and largest GWAS summary statistics (GSCAN 7 ) for smoking behaviors, we applied gene set association and heritability enrichment analyses to specifically test the contribution of these particular genes to four smoking behaviors: smoking initiation, age of initiation, cigarettes per day, and smoking cessation.
METHODS:
We used Multi-marker Analysis of GenoMic Annotation 15 (MAGMA) to test gene-level associations of the Smokescreen and Nicotinic gene sets with four smoking behaviors: lifetime smoking initiation, age of smoking initiation, cigarettes per day, and smoking cessation. We used summary statistics from Liu et al. 7 , minus the 23andMe data, and full descriptions of the phenotypes can be found in reference 7 . We included a control phenotype, alcoholic drinks per week, which was also a GSCAN phenotype. SNP-based genetic correlations 7 with smoking phenotypes range from 0.1-0.34. While it can be viewed as an addiction-related phenotype 16 , is distinct from smoking behaviors and thus provides an assessment of whether the particular gene sets relate to smoking phenotypes or more generally addiction-related behaviors. These summary statistics correspond to sample sizes of 632,802; 262,990; 263,954; 312,812; and 537,349 individuals for the five phenotypes, respectively.
We applied the competitive MAGMA test to determine whether the gene sets of interest were more strongly associated with these phenotypes than the rest of the genome. We tested two smoking-related gene sets. First, we tested the set of 1,031 addiction genes included on the Smokescreen Genotyping Array 9 (hereafter referred to as the 'Smokescreen' gene set), of which 1,009 were also tagged by variants with GWAS summary statistics from GSCAN. These genes were chosen based on bioinformatic databases and expert curation, being characterized as 'addictionrelevant' genes; a full description of the Smokescreen array can be found in Bauerly et al. 9 The second smoking-relevant gene set was comprised of 107 expert-curated nAChR-related genes that are directly involved in signaling through nAChRs as identified by Melroy-Greif et al. 13 (hereafter the 'Nicotinic' gene set). Thirty-six genes were present in both the Smokescreen and Nicotinic gene sets.
We also tested three control gene sets, that were predicted to show no association with smoking behaviors based on patterns of genetic correlation as presented by Liu et al. 7 : height (444 genes; r g ~ -0.10 -0.04), Alzheimer's (476 genes; r g ~ -0.06 -0.08), and inflammatory bowel disease (234 genes; r g ~ -0.05 -0.04). These served as negative controls, not expected to have substantial genetic overlap with smoking behaviors. Control sets of genes were identified by querying the GWAS Catalog (https://www.ebi.ac.uk/gwas/) for the terms "height", "Alzheimer's", and "inflammatory bowel disease", identifying all the gene names tagged by GWAS Catalog as being associated with these traits, and then aggregating these genes into gene sets. As the Nicotinic genes included only protein-coding genes, we excluded pseudogenes, ncRNA genes, lncRNA genes, and miRNA genes from all control gene sets.
In all analyses, variants were annotated to genes using a 25Kb window around the start and end point of each gene in MAGMA in an attempt to include variants that might exert close-range regulatory effects (e.g., within promoter regions) as in previous gene set analyses 17 . We included the default covariates in MAGMA (gene size, density, inverse MAC, per-gene sample size, plus the log value of each) to control for possible confounding factors. We tested five gene sets for each phenotype; therefore, we applied a Bonferroni multiple testing correction for significance for five tests as the within-trait significance threshold (α=0.01). Following the competitive tests described above, we performed conditional tests of within-trait significant gene sets. These assessed whether the association of a target gene set for a particular phenotype was significant conditional on the effects of additional gene sets. First, we tested the association of the Nicotinic genes conditional on the effects of the Smokescreen genes, which allowed us to determine whether the effects of the Nicotinic genes were simply the effect of genes shared between the two gene sets. Next, we examined the association of the Smokescreen gene set conditional on the Nicotinic gene set. Since no control gene set analysis passed our within-trait Bonferroni significance threshold, we did not evaluate conditional associations of those. In total we performed seven conditional tests and used a Bonferroni correction for seven tests (α=0.00714).
Finally, we performed an enrichment analysis of the heritable contribution of each gene set, relative to the number of markers in the gene set, using partitioned LD score regression 18 (LDSC).
We added annotations for each of the five gene sets listed above to the baseline with LD annotation model 19 , as suggested in the LDSC documentation. We applied a within-trait Bonferroni correction for these enrichment analyses based on five gene sets for each phenotype (α=0.01).
RESULTS:
We found that the smoking gene sets (Smokescreen and Nicotinic) were significantly associated with the four smoking phenotypes, but not the control addiction-related phenotype, drinks per week ( Fig. 1, Suppl . Table 1 ). While both smoking gene sets were significantly associated with cigarettes per day, smoking initiation, and smoking cessation, age of initiation was only associated with the Smokescreen dataset. None of the negative control gene sets was significantly associated with any phenotype (all p>0.01).
Many genes were present in more than one gene set (36 overlapped between the Nicotinic and Smokescreen gene sets), and 128 individual genes from one or more gene sets were individually significantly associated with one or more phenotypes (Suppl. Table S2 ). 19 of these were within the Nicotinic gene set, 61 were within the Smokescreen set, and nine of these overlapped (Suppl . Table   S2 ). Thus, though the trait genetic correlations are very weak, some of these genes are likely to influence multiple traits (Suppl . Table S2 ).
To test whether the smoking gene sets were independently associated with smoking phenotypes, or if the associations for each resulted from the genes overlapping genes in both gene sets, we performed conditional analyses (Table 1) Next, we used LDSC to estimate the total SNP-heritability (h 2 SNP ) for each smoking phenotype. Table 2 ). The Nicotinic gene set was significantly enriched only for smoking cessation. Although Nicotinic gene set enrichment estimates for all phenotypes were comparatively high (ranging from 1.59-3.27; Table 2 ), the relatively small number of genes, and therefore small number of variants as a proportion of all variants, led to high uncertainty in these estimates. The
Nicotinic gene set enrichment standard errors were generally the largest and limited our statistical power to detect enrichment ( Table 2 ). None of the control gene sets were significantly enriched for any trait. Overall, the enrichment analyses indicated that the genes present on the Smokescreen array are indeed enriched for smoking-relevant genetic variants, and that at least some of the genetic signal in smoking phenotypes comes from variants within the nicotinic receptors and genes they interact with. However, these gene sets cumulatively explain a small percentage of h 2 SNP ; less than 3% of h 2 SNP is attributable to Nicotinic genes, and less than 13% is attributable to all of the Smokescreen genes (Table 2) .
DISCUSSION:
We examined the genes on the Smokescreen Genotyping Array and those involved with nicotinic receptors to assess whether they are associated with smoking phenotypes, and the degree to which they contribute to variation in the behavior (h 2 SNP ). Both sets of genes were significantly associated with at least some of the tested smoking phenotypes. This is in contrast to the previous study of nicotinic genes by Melroy-Greif et al. 13 . However, the GSCAN summary statistics utilized a sample an order of magnitude larger than was available earlier, suggesting that the previous lack of gene set associations was due to low power. Additional associations of the Nicotinic genes may be found with larger sample sizes, though the partitioned LDSC analyses suggest that the nicotinic receptors and the genes they interact with cumulatively account for only 1.6-2.8% of h 2 SNP . This implies in combination with other studies (e.g., Liu et al. 7 ) that although the nicotinic receptors are influential in smoking behaviors and play a key physiological role in response to nicotine, much of the genetic variation in these phenotypes is due to other pathways, consistent with a highly polygenic model of these complex traits.
Smokescreen incorporated roughly ten times the number of genes compared to the Nicotinic receptors, and accordingly accounted for a larger proportion of h 2 SNP , up to 12% of the genetic variance tagged by genome-wide markers. However, much of the genetic variance in smoking phenotypes remains unaccounted for by these variants and genes, and must be attributable to genes . Table S1 ), specific genes within each set are clearly still contributing to variation in smoking behaviors. For predictive purposes and individualized treatment for nicotine use, additional variants outside of classical 'addiction genes,' including nicotinic receptors, will need to be considered.
Our study was limited to the GSCAN sample 7 , restricted to only those of European ancestry, and no independent replication samples are available. Furthermore, while GSCAN contains the currently largest available sample for summary statistics, we were limited to those excluding 23andMe data, and increasing the sample size would likely increase our power to detect gene set associations.
However, this is unlikely to substantially change our conclusions, particularly as LDSC-based h 2 SNP estimates indicate that these genes collectively account for a small proportion of the genetic variance.
Notably, the GSCAN performed GWAS of common variants only, and thus the gene set associations and h 2 SNP estimates presented here are restricted to the influence of common variants. Rare variants within genes of these gene sets may influence smoking behaviors and therefore these genes may yet have a larger role in smoking behavior than these analyses suggest. However, even if this is the case, it is unlikely that rare variant h 2 SNP would account for the large discrepancy between current total h 2 SNP estimates and twin-based h 2 .
Smoking is one of the leading cause of premature death in the United States 1 , and new forms of nicotine use, such as e-cigarettes, have gained prominence 3 . There remains, therefore, a critical need to understand the underlying biology of nicotine use, and identifying key genes and sets of genes is one possible avenue toward this goal. Nicotinic acetylcholine receptors play a key role as the binding sites for nicotine and the genes with which they interact influence smoking behaviors, as do genes traditionally thought of as 'addiction' genes. However, while these loci influence genetic variation in smoking behaviors, it is clear that these specifically targeted genes do not yet account for a large proportion of the heritability in smoking, and will therefore be of limited use for predictive purposes 20 . Ever-larger association studies, beyond GSCAN 7 , will be instrumental for this purpose, by examining genome-wide, unascertained markers in combination with improved statistical power as well as incorporating other 'omics datasets and advanced methodologies to go beyond positional mapping, such as imputing genetically-regulated gene expression 21 or integrating information from animal models of addiction.
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